[Development of a rapid chimeric antigen receptor (CAR)-T production process and assessment of critical quality attributes].

[In vivo CAR-T cells: When the patient becomes their own factory].

The main delivery platforms under clinical investigation are described, focusing on lentiviral vectors and lipid nanoparticles, and their differences in terms of mechanisms of action, associated risks, and optimization strategies are discussed.

Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review

In vivo CAR‑T therapy: recent progress and future directions

In vivo CAR-T is poised to broaden the reach of cellular immunotherapy, provided that its development is guided by rigorous pharmacology, chemistry, manufacturing and controls, and long-term molecular safety surveillance.

In vivo CAR T cells on the highway: a roadmap for the next decade

Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.

In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of several hematological malignancies, but its broader application remains constrained by the complexity, cost, and time required for conventional ex vivo manufacturing. In vivo CAR T-cell therapy has emerged as a promising next-generation str...

Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation

Chimeric antigen receptor T‐cell (CAR‐T) therapy is a transformative tumor immunotherapy that redirects autologous T cells to eliminate malignant cells. However, its broader clinical translation is constrained by complex and costly ex vivo manufacturing, variable product quality, and limited control over in vivo activi...